Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis
Year: 2013
Type: article
Abstract: Erythropoietin (Epo) is used in clinical settings to enhance hematopoietic function and to improve the quality of life for patients undergoing chemotherapy by reducing fatigue and the need for transfusions. However, several meta-analyses have revealed that Epo treatments are associated with an increased risk of mortality in cancer patients. In this study, we examined the role of Epo in prostate cancer (PCa) progression, using in vitro cell culture systems and in vivo bone metastatic assays. We found that Epo did not stimulate the proliferation of PCa cell lines, but did protect PCa cells from apoptosis. In animal models of PCa metastasis, no evidence was found to support the hypothesis that Epo enhances metastasis. Together, these findings suggest that Epo may be useful for treating severe anemia in PCa patients without increasing metastatic risk.
Source: Journal of Cellular Biochemistry
DOI: 10.1002/jcb.24592
Institutions: University of Michigan, Michigan Medicine
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1165598027, G1171586233, G1404790370, G1457163447, G1562841778, G1591233083, Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche, G2585515454, The Biology of Prostate Cancer Skeletal Metastases, G3711721818, G474356801, G7122925669, G740717484, G9000009177, G9000014577, G9000146432, G9000265101, G9000329101
OpenAlex ID: W1931101846